Abstract Number: 1757 • 2017 ACR/ARHP Annual Meeting
Rituximab for Induction and Maintenance Therapy of Granulomatosis with Polyangiitis: A Single-Center Cohort Study on 114 Patients
Background/Purpose: Randomized–controlled trials (RCTs) showed rituximab’s (RTX) noninferiority to cyclophosphamide for induction therapy of severe ANCA-associated vasculitides and significantly lower relapse rate than azathioprine maintenance.…Abstract Number: 1765 • 2017 ACR/ARHP Annual Meeting
Validation of the ACR EULAR Provisional 2017 Classification Criteria of Granulomatosis with Polyangiitis (GPA) Amongst Patients with ANCA Associated Vasculitis
Background/Purpose: The purpose of this study was to validate the recently proposed ACR EULAR 2017 classification criteria of GPA in a real life cohort of…Abstract Number: 1770 • 2017 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitis (AAV) in Younger Vs Older Patients: Comparison of Clinical, Serologic and Outcome Differences and Their Implications for Management
Background/Purpose: ANCA-associated vasculitis (AAV) is a cause of multi-organ disease in all ages, but peaks at ages 65-74. Limited data is available on the characteristics…Abstract Number: 1777 • 2017 ACR/ARHP Annual Meeting
Incidence and Prevalence of Granulomatosis with Polyangiitis and Microscopic Polyangiitis in a Health Management Organization: A 15-Year Study
Background/Purpose: ANCA-associated vasculitides are rare diseases and epidemiological data on them is scarce. Our objective was to estimate incidence and prevalence rates of Granulomatosis with…Abstract Number: 1847 • 2017 ACR/ARHP Annual Meeting
The IgG4:IgG RNA Ratio in Peripheral Blood Perfectly Differentiates Active Disease from Remission in Granulomatosis with Polyangiitis. a New Disease Activity Marker?
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is characterized by vasculitis in lungs, kidneys and the ear, nose and throat region. Regular monitoring and treatment adjustments are…Abstract Number: 1948 • 2016 ACR/ARHP Annual Meeting
Evaluation of Body Composition Parameters in Granulomatosis with Polyangiitis: Association of Fat Mass Parameters with Disease Activity and Inflammatory Markers
Background/Purpose: Granulomatosis with polyangiitis (GPA, Wegener´s) patients are more exposed to traditional cardiovascular risk factor, including obesity. In rheumatic diseases, inflammation has been associated with…Abstract Number: 1954 • 2016 ACR/ARHP Annual Meeting
Clinical Features and Long Term Outcome of 105 Patients of Granulomatosis with Polyangiitis: A Single Centre Experience from North India
Background/Purpose: The published Indian data on Granulomatosis with Polyangiitis (GPA) is sparse and only in the form of few small case series. The purpose of this study…Abstract Number: 2079 • 2016 ACR/ARHP Annual Meeting
Incidence and Risk of Pneumocystis Jirovecii Pneumonia Following Rituximab Treatment in Granulomatosis with Polyangiitis in the United States: An Analysis from a National Database
Background/Purpose: Pneumocystis Jirovecii pneumonia (PJP) is a life-threatening complication in granulomatosis with polyangiitis (GPA). Guidelines from EULAR for ANCA-associated vasculitis (AAV) recommend institution of PJP…Abstract Number: 1930 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis
Background/Purpose: Factors associated with cumulative glucocorticoid exposure in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) have not previously been described. We examined the association…Abstract Number: 1936 • 2016 ACR/ARHP Annual Meeting
Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study
Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is…Abstract Number: 853 • 2015 ACR/ARHP Annual Meeting
Evaluation and Validation of Case-Finding Algorithms for the Identification of Patients with Granulomatosis with Polyangiitis in Large Healthcare Administrative Databases
Background/Purpose: To facilitate clinical care and research, validated algorithms are needed to accurately identify patients with granulomatosis with polyangiitis (GPA; Wegener's). This study, sought to…Abstract Number: 864 • 2015 ACR/ARHP Annual Meeting
Anticytokine Autoantibody Profiling in Five Types of Systemic Vasculitis
Background/Purpose: Anticytokine autoantibodies (ACAs) are pathogenic in many hematologic, pulmonary and infectious diseases. Evaluation in autoimmune diseases, including systemic lupus erythematosus (SLE), shows that ACAs…Abstract Number: 870 • 2015 ACR/ARHP Annual Meeting
Development of an Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Patient-Reported Outcome Measure: Identification of Salient Themes and Candidate Questionnaire Item Development
Background/Purpose: Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs), including granulomatosis with polyangiitis (Wegener's, (GPA), eosinophilic granulomatosis with polyangiitis (Churg-Strauss, EGPA), and microscopic polyangiitis (MPA),…Abstract Number: 877 • 2015 ACR/ARHP Annual Meeting
Improved Survival in Granulomatosis with Polyangiitis: A Population-Based Study
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is associated with an increased risk of mortality. However, recent mortality trends in GPA are largely unknown, particularly in the…Abstract Number: 888 • 2015 ACR/ARHP Annual Meeting
Plasma Exchanges to Treat Primary Systemic Necrotizing Vasculitides: Data from a French Nationwide Study
Background/Purpose: Plasma exchange (PE) is usually used to treat severe primary systemic necrotizing vasculitides (SNVs) and/or virus-induced vasculitides. Only severe renal insufficiency (serum creatinine (SCR)…